Form 4: Kymera Therapeutics COO Sells Shares to Cover Tax Obligations

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, sold 2,575 shares of common stock on May 23, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On May 23, 2024, Jeremy G. Chadwick, the Chief Operating Officer of Kymera Therapeutics, Inc. (KYMR), sold 2,575 shares of common stock.
• The sale was executed at a weighted average price of $34.9921 per share, with individual transactions ranging from $34.65 to $35.2963.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Chadwick directly owns 44,183 shares of Kymera Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock sale for tax obligations) by a company executive. It doesn't inherently indicate positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. This transaction reflects a standard part of executive compensation and financial planning.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a common occurrence across the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen often see similar transactions by their executives.
• These sales are typically viewed as routine and don't necessarily indicate a change in the executive's confidence in the company's future prospects.

Stakeholder Impact

• The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates